- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03528863
Web-based Mindfulness Meditation in Reducing Distress in Participants With Metastatic Gastrointestinal Cancer and Their Caregivers
Being Present 2.0: Web-Based Mindfulness Meditation for Gastrointestinal Cancer Patients and Caregivers
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
PRIMARY OBJECTIVES:
I. To determine the feasibility and acceptability of an 8-week web-based mindfulness meditation program with live webinars among patients with a metastatic gastrointestinal (GI) cancer receiving chemotherapy and their caregivers.
SECONDARY OBJECTIVES:
I. Estimate the efficacy of an 8-week web-based mindfulness meditation program with live webinars among patients with a metastatic GI cancer receiving chemotherapy and their caregivers.
OUTLINE:
Participants practice with web-based mindfulness meditation over 10-15 minute guided audio sessions for 5 days a week for 8 weeks. Participants also attend meditation webinars over 60 minutes once a week, for 8 weeks.
After completion of study, participants are followed up at 8 weeks.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
California
-
San Francisco, California, États-Unis, 94115
- University of California, San Francisco
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- ELIGIBLE PATIENTS: Carry a diagnosis of a metastatic GI cancer
- ELIGIBLE PATIENTS: Anticipate receiving chemotherapy for at least 12 weeks total from the time of recruitment
- ELIGIBLE PATIENTS: Have an estimated life expectancy of at least 6 months, assessed by principal investigator or treating investigator
- ELIGIBLE PATIENTS: Have an Eastern Cooperative Oncology Group (ECOG) performance status between 0-2
- ELIGIBLE PATIENTS: Be able to speak and read English
- ELIGIBLE PATIENTS: Be able to navigate websites, fill out forms on the web, communicate by email, and have regular access to the internet (assessed by participant self-report)
- ELIGIBLE PATIENTS: Have daily access to a mobile phone capable of receiving text messages, as determined by a study investigator
- ELIGIBLE PATIENTS: Be able to provide informed consent
- ELIGIBLE CAREGIVERS: Be a spouse/partner, other family member, or a close friend of a patient who consented to participate in the Being Present 2.0 study
- ELIGIBLE CAREGIVERS: Be able to speak and read English
- ELIGIBLE CAREGIVERS: Be able to navigate websites, fill out forms on the web, communicate by email, and have regular access to the internet (assessed by participant self-report)
- ELIGIBLE CAREGIVERS: Have access to a mobile phone capable of receiving text messages, as determined by a study investigator
- ELIGIBLE CAREGIVERS: Be able to provide informed consent
Exclusion Criteria:
- Have a current meditation practice (> 2 episodes or > 1 hour total, weekly)
- Be currently enrolled in a stress reduction program
- Have extensive hearing loss such that ability to participate in the study would be impaired
- Have participated in the original Being Present pilot study (BP1)
- Be caregivers of patients who decline Being Present 2.0 (BP2) study participation
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Supportive Care (web-based mindfulness meditation)
Participants practice with web-based mindfulness meditation over 10-15 minute guided audio sessions for 5 days a week for 8 weeks.
Participants also attend meditation webinars over 60 minutes once a week, for 8 weeks.
|
Etudes annexes
Receive web-based mindfulness meditation
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Feasibility as assessed by evaluating recruitment rate
Délai: At end of enrollment (Up to 1 year)
|
Number of participants approached who consent to participate
|
At end of enrollment (Up to 1 year)
|
|
Feasibility as assessed by evaluating rate of refusal to participate
Délai: At end of enrollment (Up to 1 year)
|
Number of participants refusing to consent.
|
At end of enrollment (Up to 1 year)
|
|
Feasibility as assessed by rate of attrition
Délai: At 8 weeks post end of enrollment (Up to 1 year)
|
Number of participants dropping out after start of intervention for any reason.
|
At 8 weeks post end of enrollment (Up to 1 year)
|
|
Acceptability as assessed by adherence to practice instructions
Délai: At 8 weeks after study start (Up to 1 year)
|
Number of times participant practices during study, documented via website data capture
|
At 8 weeks after study start (Up to 1 year)
|
|
Acceptability as assessed by adherence to practice instructions
Délai: At 8 weeks after study start (Up to 1 year)
|
Number of times participant watches recorded webinars, documented via website data capture
|
At 8 weeks after study start (Up to 1 year)
|
|
Acceptability as assessed by adherence to practice instructions
Délai: At 8 weeks after study start (Up to 1 year)
|
Number of times patient participates in live webinars, documented via roll-call.
|
At 8 weeks after study start (Up to 1 year)
|
|
Acceptability as assessed by adherence to practice instructions
Délai: At 8 weeks after study start (Up to 1 year)
|
Average duration of meditation session (measured in minutes), documented via website data capture.
|
At 8 weeks after study start (Up to 1 year)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Efficacy as assessed by National Comprehensive Cancer Network (NCCN) Distress Thermometer
Délai: At baseline, week 4 and week 8 after study start (Up to 1 year)
|
0 to 10, with 10 being the worst level of distress
|
At baseline, week 4 and week 8 after study start (Up to 1 year)
|
|
Efficacy as assessed by National Institutes of Health Patient Reported Outcomes Measurement Information System (NIH PROMIS)
Délai: At baseline, week 4 and week 8 after study start (Up to 1 year)
|
At baseline, week 4 and week 8 after study start (Up to 1 year)
|
|
|
Efficacy as assessed by a Five Facet Mindfulness Questionnaire Short (FFMQ-SF)
Délai: At baseline, week 4 and week 8 after study start (Up to 1 year)
|
At baseline, week 4 and week 8 after study start (Up to 1 year)
|
|
|
Efficacy as assessed by a "Are You at Peace?" one-item spiritual probe
Délai: At baseline, week 4 and week 8 after study start (Up to 1 year)
|
At baseline, week 4 and week 8 after study start (Up to 1 year)
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Chloe Atreya, MD, University of California, San Francisco
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 174534 (Integrated Research Application System)
- NCI-2018-00622 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .